Neuralstem’s ALS Trial On Clinical Hold

Neuralstem, Inc. (NYSE Alternext US: CUR) announced its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations for modifications to its protocol. "The FDA has presented us with their review of our entire Investigational New Drug (IND) application," said Richard Garr, Neuralstem's President & CEO.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.